Quarterly ResultAug 5, 2026, 04:56 PM
Novanta Q2 Revenue $266M, EPS $0.30; Raises FY26 Guidance
AI Summary
Novanta Inc. reported strong financial results for the second quarter of 2026, with GAAP revenue increasing 10% to $266 million and GAAP diluted EPS at $0.30. The company also announced the recent acquisition of Riverpoint Medical, which is expected to significantly boost its medical consumables business and overall medical end-market exposure. Consequently, Novanta raised its full-year 2026 guidance, anticipating GAAP revenue between $1,130 million and $1,140 million.
Key Highlights
- Q2 2026 GAAP Revenue increased 10% to $266 million.
- Q2 2026 GAAP Diluted EPS was $0.30; Adjusted Diluted EPS rose 17% to $0.89.
- Q2 2026 Adjusted EBITDA increased 16% to $61 million.
- Acquired Riverpoint Medical, doubling medical consumables business to ~25% of sales.
- Raised full-year 2026 GAAP revenue guidance to $1,130M-$1,140M (15%+ growth).
- Full-year 2026 Adjusted EBITDA guidance raised to $273M-$278M (24%+ growth).
- Q2 Automation Enabling Technologies revenue was $136.2 million.
- Q2 Medical Solutions revenue was $129.6 million.
Price Impact
More from NOVT